Kantonsspital, St. Gallen

Erythema multiforme-like reaction to adalimumab reported

Published in Oncology Business Week, July 25th, 2004

A pathological skin reaction to adalimumab has been reported.

"The tumor necrosis factor alpha (TNF-alpha) inhibitors etanercept and infliximab have shown good clinical results in the treatment of rheumatoid arthritis and other autoimmune disorders," rheumatologists in Switzerland noted. "With these novel fusion proteins, immune-mediated side effects, among them various cutaneous reactions, have been encountered."

W. Beuthien and colleagues working at Kantonsspital St. Gallen described "an erythema multiforme-like skin reaction to treatment with the monoclonal anti-TNF-alpha antibody adalimumab in a patient with rheumatoid arthritis."

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Oncology Business Week

Source: Oncology Business Week (2004-07-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry